Way back in 2019, before most of us knew what a shroom stock was, MindMed made one of the first big moves in the psychedelic medicine industry by acquiring a drug candidate based on Ibogaine. The drug was 18-MC, a version of Ibogaine synthesized to be non-hallucinogenic while maintaining the medicine’s anti-addictive properties.
This was before any psychedelic medicine companies has gone public and MindMed began its journey here, with the acquisition of this anti-addiction compound.
Today, many years and market runs later, MindMed is finally moving this compound towards Phase 2 trials.
The Phase 1 results showed positive safety and tolerability results, the main objective of this phase of the trial process (and an important hurdle considering that natural Ibogaine has a history of adverse physical effects). See below for the full topline results.
According to MindMed, Phase 2a trial remains on track to start in Q2 2022. This follows on the heels of MindMed’s positive Phase 2 results using LSD for anxiety, giving the firm two Phase 2 trials for major conditions underway this year.
Stay tuned for more as it comes.
NEWS PROVIDED BY
May 19, 2022, 07:30 ET
– Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal
– Phase 2a trial remains on track to initiate in Q2 2022
NEW YORK, May 19, 2022 /CNW/ — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.
The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal. MM-110 (also known as zolunicant HCl or 18-MC) is an α3β4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.
“As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal,” said Daniel R Karlin, MD MA, Chief Medical Officer of MindMed. “These data build on extensive pharmacology and toxicology studies, as well as encouraging results from preclinical studies that showed reductions in translational markers of opioid withdrawal and multi-day reductions in opioid self-administration following a single-dose administration of MM-110. Together, the data generated to date support our clinical development program and bring us one step closer to…
Read more:MindMed Releases Phase 1 Trial Results For Opioid Addiction | Microdose